Autolus Therapeutics PLC AUTL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/06/24 EDT
4.08quote price arrow down-0.11 (-2.63%)
Volume
2,018,865
52 week range
1.79 - 7.45
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.08
  • 52 Week High7.45
  • 52 Week High Date01/12/24
  • 52 Week Low1.79
  • 52 Week Low Date05/12/23

Key Stats

  • Market Cap1.085B
  • Shares Out265.93M
  • 10 Day Average Volume3.33M
  • Dividend-
  • Dividend Yield-
  • Beta2.01
  • YTD % Change-36.65

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.08
  • 52 Week High7.45
  • 52 Week High Date01/12/24
  • 52 Week Low1.79
  • 52 Week Low Date05/12/23
  • Market Cap1.085B
  • Shares Out265.93M
  • 10 Day Average Volume3.33M
  • Dividend-
  • Dividend Yield-
  • Beta2.01
  • YTD % Change-36.65

RATIOS/PROFITABILITY

  • EPS (TTM)-1.20
  • P/E (TTM)-3.41
  • Fwd P/E (NTM)-6.04
  • EBITDA (TTM)-168.928M
  • ROE (TTM)-101.61%
  • Revenue (TTM)1.698M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-12,272.26%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/14/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Autolus Therapeutics PLC

 

Profile

MORE
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their...
Michael Bonney
Chairman of the Board
Christian Itin Ph.D.
Chief Executive Officer, Executive Director
Christopher Vann
Chief Operating Officer, Senior Vice President
Lucinda Crabtree Ph.D.
Chief Financial Officer, Senior Vice President
Address
The Mediaworks, 191 Wood Lane
London
W12 7FP
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
PLRX
Pliant Therapeutics Inc
13.79-0.19-1.36%
IRON
Disc Medicine Inc
30.17+0.38+1.28%
DNTH
Dianthus Therapeutics Inc
23.92-1.88-7.29%
HLVX
Hillevax Inc
13.80+0.19+1.40%
STOK
Stoke Therapeutics Inc
11.87-0.15-1.25%